Summit Financial LLC Has $7.03 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Financial LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,008 shares of the biopharmaceutical company's stock after buying an additional 1,650 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 0.5% of Summit Financial LLC's portfolio, making the stock its 29th biggest position. Summit Financial LLC's holdings in Regeneron Pharmaceuticals were worth $7,034,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $37,000. Finally, Bruce G. Allen Investments LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $40,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $12.82 during mid-day trading on Wednesday, hitting $903.48. 594,852 shares of the stock traded hands, compared to its average volume of 492,602. The business's 50-day moving average price is $945.77 and its 200 day moving average price is $895.19. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The company has a market cap of $99.17 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the business earned $10.96 EPS. The business's revenue for the quarter was up .6% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Marion Mccourt sold 1,000 shares of the company's stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company's stock, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares of the company's stock, valued at $17,540,472.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,195 shares of company stock worth $9,759,898. Insiders own 8.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Royal Bank of Canada restated an "outperform" rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a research report on Tuesday, January 23rd. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 13th. Bank of America boosted their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a research report on Friday, April 12th. Finally, Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.